Medical monitoring

Senseonics to Participate in the H.C. Wainwright Global Life Sciences Conference

Tuesday, March 2, 2021 - 10:29pm

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Life Sciences Conference.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Life Sciences Conference.
  • Management is scheduled to participate and hold one-on-one meetings Tuesday, March 9, 2021.
  • A presentation webcast will be available in advance of the event on the same morning at 7:00am ET.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Hucu.ai Partners With Nonnatech To Reimagine Remote Patient Monitoring

Tuesday, March 2, 2021 - 4:00pm

Together, Hucu.ai and Nonnatech offer a comprehensive solution to be able to quickly share relevant monitoring data with other stakeholders (PCPs, specialists, therapists, aids, and even families) and coordinate care most efficiently.

Key Points: 
  • Together, Hucu.ai and Nonnatech offer a comprehensive solution to be able to quickly share relevant monitoring data with other stakeholders (PCPs, specialists, therapists, aids, and even families) and coordinate care most efficiently.
  • Nonnatech is a scalable remote patient monitoring (RPM) platform, leveraging unobtrusive wireless sensors to remotely monitor the health of patients.
  • Gary German, CEO of Nonnatech, added: "With this partnership, clinicians across different organizations can communicate with each other in the context of a patient they are monitoring remotely.
  • About Nonnatech: Founded on proactive care, Nonnatech uses predictive analytics, specialized monitoring capabilities, and alerts to track patients and reduce hospitalizations.

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

Tuesday, March 2, 2021 - 3:00pm

The pre-planned futility analysis was conducted by Orbus Independent Data Monitoring Committee (IDMC), an independent panel of experts that periodically monitors the safety and efficacy of the STELLAR study.

Key Points: 
  • The pre-planned futility analysis was conducted by Orbus Independent Data Monitoring Committee (IDMC), an independent panel of experts that periodically monitors the safety and efficacy of the STELLAR study.
  • The study reached a pre-specified number of events required for the futility analysis.
  • For this pre-planned interim analysis for futility, the IDMCs recommendation to continue the study was to be based upon the hazard ratio in the STELLAR study being less than one.
  • Based on its review of the efficacy and safety data, the IDMC recommended that the STELLAR study proceed without any modifications.

CareSignal Accelerates Virtual Care, Bringing Deviceless Remote Patient Monitoring to Leading Health Systems and Integrated Delivery Networks

Tuesday, March 2, 2021 - 2:00pm

CareSignal today announced an expansion of its Deviceless Remote Patient Monitoring (RPM) offering, bringing clinically validated, scalable solutions for remote monitoring to organizations providing or planning to provide virtual patient care.

Key Points: 
  • CareSignal today announced an expansion of its Deviceless Remote Patient Monitoring (RPM) offering, bringing clinically validated, scalable solutions for remote monitoring to organizations providing or planning to provide virtual patient care.
  • The COVID-19 pandemic, along with subsequent operational shifts, have forced health care delivery away from analog and toward digital.
  • Jay Compton, managing director, Deloitte Consulting LLP, and chief technology officer, ConvergeHEALTH by Deloitte, emphasizes the timeliness of scalable, clinically actionable remote monitoring: This offering combines the best of traditional remote patient monitoring and large-scale patient engagement.
  • CareSignal is Deviceless Remote Patient Monitoring for value-based care.

Masimo Announces CE Marking of the Rad-G™ with Temperature

Tuesday, March 2, 2021 - 7:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210301006115/en/
    Masimo Rad-G with Temperature (Photo: Business Wire)
    The infrared thermometry offered by Rad-G with Temperature provides a host of benefits.
  • With the addition of temperature measurement, Rad-G is more versatile than ever, streamlining the assessment of multiple key vital signs.
  • Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet.
  • Published clinical studies on pulse oximetry and the benefits of Masimo SET can be found on our website at http://www.masimo.com .

Worldwide Blood Glucose Monitoring Devices Industry to 2028 - Increasing Awareness About Diabetes Preventive Care is Driving Growth

Friday, February 26, 2021 - 2:30pm

Chapter 4 Blood Glucose Monitoring Devices Market: Product Estimates & Trend Analysis

Key Points: 
  • Chapter 4 Blood Glucose Monitoring Devices Market: Product Estimates & Trend Analysis
    4.1 Blood Glucose Monitoring devices: Product Analysis
    4.2.2.1 Blood glucose meters market, 2016 - 2028 (USD Million)
    4.3.1 Continuous blood glucose monitoring devices market, by type, 2016 - 2028 (USD Million)
    4.3.3.1 Transmitter and receiver market, 2016 - 2028 (USD Million)
    Chapter 5 Blood Glucose Monitoring Devices Market: End-use Estimates & Trend Analysis
    5.1 Blood Glucose Monitoring Devices Market: End-use Analysis
    5.2.1 Hospitals blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    5.3.1 Home care blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    5.4.1 Diagnostic centers blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    Chapter 6 Blood Glucose Monitoring Devices Market: Regional Estimates & Trend Analysis
    6.1 Blood Glucose Monitoring Devices Market: Regional Movement Analysis
    6.2.1 North America blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.2.2.1 U.S. blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.2.3.1 Canada blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3 Europe blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.1.1 U.K. blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.2.1 Germany blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.3.1 France blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.4.1 Italy blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.5.1 Spain blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.6.1 Poland blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.7.1 Russia blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.8.1 Ukraine blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.9.1 Belarus blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.3.10.1 Turkey blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.1 Asia Pacific blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.2.1 Japan blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.3.1 China blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.4.1 South Korea blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.5.1 India blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.6.1 Australia blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.7.1 Kazakhstan blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.4.8.1 Uzbekistan blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.5.1 Latin America blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.5.2.1 Brazil blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.5.3.1 Mexico blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.5.4.1 Argentina blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.5.5.1 Colombia blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.6.1 Middle East and Africa blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.6.2.1 South Africa blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.6.3.1 Saudi Arabia blood glucose monitoring devices market, 2016 - 2028 (USD Million)
    6.6.4.1 UAE blood glucose monitoring devices market, 2016 - 2028 (USD Million)

Assure Holdings to Acquire Sentry Neuromonitoring

Thursday, February 25, 2021 - 1:30pm

DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (Term Sheet) to acquire (the Acquisition) Sentry Neuromonitoring, LLC (Sentry), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000.

Key Points: 
  • DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (Term Sheet) to acquire (the Acquisition) Sentry Neuromonitoring, LLC (Sentry), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000.
  • Under the Term Sheet, Assure will acquire Sentrys contracts, employees, business relationships and assets including accounts receivable, and assume up to $250,000 of its debt.
  • In 2020, Sentry performed more than 5,500 IONM procedures and approximately 50% ofthese procedures were commercial insurance payors.
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

Global Non-invasive Glucose Monitoring Devices Market (2021 to 2025) - Featuring Integrity Applications, Medtronic and Taiwan Biophotonic Among Others - ResearchAndMarkets.com

Wednesday, February 24, 2021 - 11:13am

The "Global Non-invasive Glucose Monitoring Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-invasive Glucose Monitoring Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The publisher has been monitoring the non-invasive glucose monitoring devices market and it is poised to grow by $ 11.35 million during 2021-2025 progressing at a CAGR of 11% during the forecast period.
  • The report on non-invasive glucose monitoring devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study identifies the integration of AI and radar technology in glucose monitoring as one of the prime reasons driving the non-invasive glucose monitoring devices market growth during the next few years.

Compass Medical Partners with CareSimple to Launch Remote Patient Monitoring Program Across its Six Massachusetts Locations

Tuesday, February 23, 2021 - 3:00pm

and NORTH PALM BEACH, Fla., Feb. 23, 2021 /PRNewswire/ -- CareSimple , the platform simplifying remote patient monitoring (RPM) for virtually all patients, and Compass Medical, PC , a physician-owned and directed medical organization, today announced the launch of their RPM collaboration across six locations in Massachusetts.

Key Points: 
  • and NORTH PALM BEACH, Fla., Feb. 23, 2021 /PRNewswire/ -- CareSimple , the platform simplifying remote patient monitoring (RPM) for virtually all patients, and Compass Medical, PC , a physician-owned and directed medical organization, today announced the launch of their RPM collaboration across six locations in Massachusetts.
  • Compass Medical originally launched its CCM offering in 2016 which began as a pilot initiative and led to a full-scale program rollout in 2017.
  • Compass Medical, PC is a physician owned and directed medical organization providing care to patients of all agesat6 different locations across southeastern Massachusetts.
  • CareSimple is an easy-to-use, secure, and scalable way to offer Remote Patient Monitoring (RPM) to at-risk patient populations.

Global Blood Glucose Monitoring Devices Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Tuesday, February 23, 2021 - 3:43pm

The "Blood Glucose Monitoring Devices Market Size, Share & Trends Analysis Report by Product (Self-monitoring, Continuous), by End-use (Hospitals, Home Care, Diagnostic Centers), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Glucose Monitoring Devices Market Size, Share & Trends Analysis Report by Product (Self-monitoring, Continuous), by End-use (Hospitals, Home Care, Diagnostic Centers), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global blood glucose monitoring devices market size is expected to reach 19.6 billion by 2028.
  • Blood glucose monitoring (BGM) devices are used to measure blood glucose levels in diabetes patients.
  • The continuous blood glucose monitoring devices segment is expected to be the fastest-growing segment during the forecast period.